{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:01:01Z","timestamp":1791223261808,"version":"4.1.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rilpivirine (RPV) is a second-generation once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown non-inferior antiviral activity to efavirenz in treatment-naive patients. Data in treatment-experienced patients are more limited. We wished to assess the efficacy and safety of a switch to RPV-based regimens in well-suppressed treatment-experienced patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between September 2012 and June 2013, all antiretroviral therapy (ART)-experienced HIV-1-infected patients with a plasma HIV RNA level &lt;50 copies\/ml, and switching to an RPV-based regimen, were analysed in this retrospective observational monocentric cohort study. The primary end point was the proportion of patients with virological success defined as a plasma HIV RNA level &lt;50 copies\/ml at 12 months using the FDA snapshot algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 281 participants were studied and 97% received a combination of RPV\/tenofovir disoproxil fumarate\/emtricitabine. At month 12, the rate of virological success was 59% and increased to 72% using available data beyond month 12. Sixteen (6%) patients experienced virological failure, which was associated with the presence of the M184V\/I resistance mutation in prior genotypes ( P=0.02) and the use of a non-NNRTI as third agent before the switch ( P=0.03). RPV-based regimens were overall well tolerated and only 23 (8%) patients discontinued ART because of adverse events, mostly neuropsychiatric adverse events. Switching to RPV was associated with significant but modest improvement of the lipid profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients fully suppressed on ART, a switch to an RPV-based regimen should only be considered in the absence of prior virological failure or resistance mutations to nucleoside reverse transcriptase inhibitors and NNRTIs to avoid virological failures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3010","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T09:08:58Z","timestamp":1447405738000},"page":"329-336","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of a Switch to Rilpivirine-Based Regimens in Treatment-Experienced HIV-1-Infected Patients: A Cohort Study"],"prefix":"10.1177","volume":"21","author":[{"given":"Sandrine","family":"Gazaignes","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Resche-Rigon","sequence":"additional","affiliation":[{"name":"Biostatistics and Computer Medicine, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"},{"name":"ECSTRA Team INSERM, UMR 1153, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gatey","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Denis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Fonsart","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristell","family":"Desseaux","sequence":"additional","affiliation":[{"name":"Biostatistics and Computer Medicine, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"},{"name":"ECSTRA Team INSERM, UMR 1153, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Guionie","sequence":"additional","affiliation":[{"name":"COREVIH Ile de France Est, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Rozenbaum","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaugerre","sequence":"additional","affiliation":[{"name":"INSERM UMR 941, Paris, France"},{"name":"Department of Virology, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris and University of Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, Assistance Publique H\u00f4pitaux de Paris, University of Paris Diderot, Paris, France"},{"name":"INSERM UMR 941, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,5,1]]},"reference":[{"key":"bibr1-IMP3010","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2254"},{"key":"bibr2-IMP3010","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"bibr3-IMP3010","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60936-7"},{"key":"bibr4-IMP3010","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824d006e"},{"key":"bibr5-IMP3010","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000169"},{"key":"bibr6-IMP3010","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000087"},{"key":"bibr7-IMP3010","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku294"},{"key":"bibr8-IMP3010","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12183"},{"key":"bibr9-IMP3010","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-216"},{"key":"bibr10-IMP3010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/hiv.12157","volume":"15","author":"Rokx C.","year":"2014","journal-title":"HIV Med"},{"key":"bibr11-IMP3010","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku187"},{"key":"bibr12-IMP3010","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000363"},{"key":"bibr13-IMP3010","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20037"},{"key":"bibr14-IMP3010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00719.x"},{"key":"bibr15-IMP3010","doi-asserted-by":"crossref","unstructured":"Crauwels H.M., van Schaick E., van heeswijk R.P.G. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC 278 in antiretroviral-naive HIV-i-infected patients in ECHO and THRIVE.\n                      10th International Congress on Drug Therapy in HIV Infection\n                      . 7\u201311 November 2010, Glasgow, UK. Poster P186.","DOI":"10.1186\/1758-2652-13-S4-P186"},{"key":"bibr16-IMP3010","unstructured":"ANRS. ANRS scale to grade the severity of adverse events in adults. (Accessed 17 March 2016.) Available from www.anrs.fr\/content\/download\/2242\/12805\/file\/ANRS-GradeEI-V1-En-2008.pdf."},{"key":"bibr17-IMP3010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","volume":"13","author":"Delaugerre C.","year":"2012","journal-title":"HIV Med"},{"key":"bibr18-IMP3010","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0293"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:32Z","timestamp":1777380752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,1]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.3851\/IMP3010"],"URL":"https:\/\/doi.org\/10.3851\/imp3010","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,1]]}}}